Compare Dolby Laboratories, Inc. (DLB) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Teladoc Health Inc — how do they compare? Dolby Laboratories, Inc. trades at $58.9 (market cap $5.47B), while Teladoc Health Inc trades at $5.54 (market cap $1.01B). The key difference: Dolby Laboratories, Inc. is far larger — about 5.4× Teladoc Health Inc's market cap, and Dolby Laboratories, Inc. pays a 2.47% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Teladoc Health Inc for 39 Days on average.
| DLB | TDOC | |
|---|---|---|
Market Cap | $5.47B | $1.01B |
Volume | 691,016 | 3,622,440 |
Sector | Technology | Health |
52-Week High | $70.09 | $9.72 |
52-Week Low | $48.51 | $4.47 |
Typical Hold Time | 98 Days | 39 Days |
Enterprise Value | $4.84B | $1.27B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals despite strong profitability margins. The company maintains robust fundamentals with 87.61% gross margins and consistent earnings beats, though revenue has plateaued around $1.3B. Recent leadership transition to Marc Whitten and expanded Meta partnership for Dolby Atmos/Vision represent key developments. Technical indicators show resistance at $59 with support at $58.
DLB offers stable cash flow generation and dividend income but faces growth challenges with flat revenue. Analyst consensus targets $90.33 (55% upside) with 47% buy ratings, though near-term execution risks and licensing volatility warrant caution. The stock presents value for income investors but requires revenue acceleration for significant appreciation.
TDOC trades at $5.56, down 3.64% today, near multi-year lows with a bearish technical outlook. The stock shows mixed fundamentals with revenue stabilizing around $2.5B but persistent net losses, though improving from 2024's $1B loss to $200M in 2025. Valuation metrics appear attractive with P/S of 0.4 and EV/EBITDA of 5.9, while analyst consensus remains cautiously optimistic with a $8.83 price target.
The outlook remains challenged by ongoing losses and BetterHelp segment weakness, but potential exists if Integrated Care profitability improves and new CFO leadership executes effectively. Key risks include sustained negative cash flow, competitive pressures, and the ongoing SEC investigation highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
